LL-37 and Magainin II cationic peptide chemistry

Cationic peptide chemistry starts with charge and amphipathy

<a href="/product/cp-034">CP-034 LL-37</a> is the verified catalog-backed target for this article. Magainin II is important in the literature as a comparator for cationic antimicrobial peptide structure, but it is not present in the verified Canada Peptides catalog. The article should therefore link LL-37 as the primary PDP, use Magainin II as a literature comparator, and document the missing SKU in the manifest rather than inventing one.

The chemistry frame is strong: both LL-37 and Magainin II are cationic, amphipathic peptides that can adopt helical conformations in membrane-mimetic environments. That makes them useful for explaining residue distribution, hydrophobic moment, charge density, CD spectroscopy, NMR structure, and model-membrane assay design. The article should remain a research reference standard guide for in-vitro work, not a finished-product or human-use page.

LL-37: cathelicidin-derived 37-residue reference standard

LL-37 is cataloged at 4493.3 Da as a cathelicidin antimicrobial peptide reference standard. At 37 residues, it is large enough to show sequence-dependent peak shape, ionisation behaviour, and secondary-structure sensitivity. A COA should confirm mass, purity, water content, residual solvents, and lot traceability. If a release file includes CD or NMR companion data, those methods should be presented as structural context, not as replacement for HPLC-MS identity.

The side-chain distribution matters. LL-37 contains multiple cationic residues and hydrophobic residues positioned to support amphipathic helix formation in membrane-mimetic systems. That does not mean the lyophilizate has one rigid solution structure under every condition. Peptide conformation depends on solvent, concentration, ionic strength, and membrane model. A good article teaches that condition dependence and then sends the reader back to the lot-specific method record.

Magainin II as a literature comparator

Magainin II is a shorter amphibian-derived cationic peptide that appears frequently in membrane-disruption literature. It is useful here because it gives readers a second architecture for understanding amphipathic helices, pore models, carpet-like surface coverage, and lipid partitioning. It should not receive a Canada Peptides product link unless the catalog is updated with a real SKU, mass, and PDP.

The article can still rank for Magainin II queries because it discusses the molecule accurately as a comparator. The reverse-index patch should not add a Magainin SKU. This preserves the no-fabrication rule and keeps CP-034 as the commercial anchor. Adjacent links to <a href="/product/cp-033">CP-033 KPV</a>, <a href="/product/cp-031">CP-031 TB-500</a>, and <a href="/product/cp-035">CP-035 GHK-Cu</a> help readers move through related repair and cationic-peptide content without implying that those SKUs are substitutes.

Methods: HPLC-MS, CD spectroscopy, and NMR answer different questions

HPLC-MS answers identity and purity questions. CD spectroscopy estimates secondary-structure content under a defined solvent or membrane-mimetic condition. NMR can assign a structure in a specific environment such as micelles. None of those methods alone proves every research use case. They work together: mass confirms the species, chromatography reports mixture composition, CD shows conformational tendency, and NMR gives high-resolution structural evidence where available.

The glossary should support this page with <a href="/glossary/cd-spectroscopy">CD spectroscopy</a>, <a href="/glossary/nmr">NMR</a>, <a href="/glossary/isoelectric-point-pi">isoelectric point</a>, and <a href="/glossary/side-chain">side chain</a>. Those terms help a procurement reader understand why a peptide can be the same SKU and still look different across assay buffers. Method context is not a detail; it is the interpretation frame.

Impurities and aggregation in cationic peptides

Cationic peptides can adsorb to plastic, interact with residual salts, and self-associate at higher concentration. A release article should explain those issues without becoming a handling protocol. The key point is that chromatographic recovery and peak shape can change with sample preparation. A broad main peak or shoulder does not automatically indicate a failed lot, but it does require method context and, ideally, MS confirmation of the integrated peak.

Oxidation and deamidation should also be considered where sequence permits. LL-37 impurity review should be anchored to its exact sequence and the lot COA, not to a generic antimicrobial peptide expectation. Magainin II literature can teach general membrane-peptide behaviour, but it cannot stand in for CP-034 lot release evidence.

Internal linking strategy for the repair cluster

The ADD entry should attach this article to CP-034. UPDATE entries can attach it to CP-033, CP-031, and CP-035 because those pages sit in adjacent repair, cationic, or short-peptide research clusters. Article links should point to <a href="/research-guide/epitalon-tb500-nad-reference-standards">Epitalon, TB-500, and NAD+ reference standards</a> and <a href="/research-guide/ghk-cu-copper-peptide-complexes">GHK-Cu copper peptide complex chemistry</a>. That gives the orphaned antimicrobial page enough context without creating an unsupported product family.

The article should state that Canada Peptides supplies HPLC-MS verified research reference standards from Toronto and that CP-034 is for in-vitro research. It should also preserve the compliance phrase: for in-vitro research use only and not for human or veterinary use. The page can be technical and search-relevant without drifting into claims about outcomes.

Summary

LL-37 is the catalog-backed SKU for this cationic peptide article. Magainin II is included as a literature comparator only because no verified CP SKU exists locally. The chemistry story is charge distribution, amphipathic helix formation, method dependence, and COA interpretation.

The article closes CP-034 coverage while protecting the catalog from invented links. It also gives the glossary a strong reason to define CD spectroscopy, NMR, side-chain charge, and aggregation in terms that procurement readers can use.

Release-file review checklist

For release-file review, keep the chemistry anchored to the verified SKU list: CP-034, CP-033, CP-031, CP-035. Confirm sequence or scaffold, molecular weight, HPLC-MS verified identity, counter-ion or modification state, water content, and residual-solvent method before copying the article into a production CMS. Canada Peptides should keep each inline product reference tied to the lower-case PDP route and should keep the article language limited to research reference standard selection, analytical characterisation, and procurement traceability. If a future catalog update changes a molecular weight, adds a salt form, or introduces a new related product, revise the cross-links and the patch file before publication rather than editing the claim in isolation.

Human review should confirm whether Magainin II is planned for the catalog. Until a verified SKU exists, the article must not add a product-page link for it.

Procurement traceability notes

A procurement reader should be able to move from this article to a PDP, from the PDP to a lot COA, and from the COA to a reproducible method record without guessing. That means names, SKU codes, molecular weights, and analytical terms must stay consistent across the article body, glossary, and reverse-index patch. The article should therefore be handled as a controlled content asset: update the reviewed date, check the DOI links, rerun the banned-phrase scan, and confirm the article still links to at least three product pages and two research-guide resources before publication.

Publication integration notes

The antimicrobial peptide page has one verified commercial anchor: CP-034 LL-37. Magainin II is useful because it is a classic literature comparator for cationic amphipathic peptide structure, but it should not appear in relatedSKUs and should not receive a PDP link. The article can still satisfy the scientific intent by explaining charge density, amphipathic helices, membrane-mimetic methods, CD spectroscopy, NMR, and HPLC-MS identity.

The editor should watch the repair-cluster links. CP-033, CP-031, and CP-035 can be UPDATE links because they help readers move through short peptide, larger peptide, and copper-complex content. They are not substitutes for LL-37. The page should make that distinction clear by keeping CP-034 in the opening, keeping Magainin II as a literature comparator, and keeping all adjacent SKUs in a cross-linking role. That gives Canada Peptides long-tail coverage for antimicrobial peptide chemistry while protecting catalog integrity.

CMS acceptance notes

Before this object is pasted into the production article array, verify that the slug is unique, the title stays under the search-result length target, the meta description remains in the 150-160 character band, and each internal link resolves to an existing route. Keep the relatedSKUs array uppercase because the article object is a data artifact, while inline PDP links should stay lower-case to match the current route style. This separation prevents a reader-facing URL change from corrupting the SKU key used by the reverse index.

The publication checklist should be mechanical. Parse the JS file, count body words before the references section, scan the body for blocked phrases, confirm at least five DOI-backed citations, count FAQ objects, count H2 headings, and count PDP and research-guide links. Then compare the article's SKU list with pdp_to_article_map_v3_patch.json. If the content and patch disagree, fix both in the same edit. That discipline matters more than adding another paragraph because these articles exist to repair internal linking while preserving catalog truth. The final editorial read should also compare the article card summary against the first body section. The two should support the same search intent, use the same verified SKU set, and avoid introducing a molecule or method that is absent from the saved patch file.

References

1. Zasloff, M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proceedings of the National Academy of Sciences, 84(15), 5449–5453. DOI: 10.1073/pnas.84.15.5449 2. Shai, Y. (2002). Mode of action of membrane active antimicrobial peptides. Peptide Science, 66(4), 236–248. DOI: 10.1002/bip.10260 3. Melo, M. N., Ferre, R., & Castanho, M. A. R. B. (2009). Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nature Reviews Microbiology, 7(3), 245–250. DOI: 10.1038/nrmicro2095 4. Porcelli, F., Verardi, R., Shi, L., Henzler-Wildman, K. A., Ramamoorthy, A., & Veglia, G. (2008). NMR Structure of the Cathelicidin-Derived Human Antimicrobial Peptide LL-37 in Dodecylphosphocholine Micelles. Biochemistry, 47(20), 5565–5572. DOI: 10.1021/bi702036s 5. Henzler Wildman, K. A., Lee, D.-K., & Ramamoorthy, A. (2003). Mechanism of Lipid Bilayer Disruption by the Human Antimicrobial Peptide, LL-37. Biochemistry, 42(21), 6545–6558. DOI: 10.1021/bi0273563 6. Henzler-Wildman, K. A., Martinez, G. V., Brown, M. F., & Ramamoorthy, A. (2004). Perturbation of the Hydrophobic Core of Lipid Bilayers by the Human Antimicrobial Peptide LL-37. Biochemistry, 43(26), 8459–8469. DOI: 10.1021/bi036284s 7. Fabisiak, A., Murawska, N., & Fichna, J. (2016). LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacological Reports, 68(4), 802–808. DOI: 10.1016/j.pharep.2016.03.015

Frequently asked questions

References

1. Zasloff, M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proceedings of the National Academy of Sciences, 84(15), 5449–5453. · link
2. Shai, Y. (2002). Mode of action of membrane active antimicrobial peptides. Peptide Science, 66(4), 236–248. · link
3. Melo, M. N., Ferre, R., & Castanho, M. A. R. B. (2009). Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nature Reviews Microbiology, 7(3), 245–250. · link
4. Porcelli, F., Verardi, R., Shi, L., Henzler-Wildman, K. A., Ramamoorthy, A., & Veglia, G. (2008). NMR Structure of the Cathelicidin-Derived Human Antimicrobial Peptide LL-37 in Dodecylphosphocholine Micelles. Biochemistry, 47(20), 5565–5572. · link
5. Henzler Wildman, K. A., Lee, D.-K., & Ramamoorthy, A. (2003). Mechanism of Lipid Bilayer Disruption by the Human Antimicrobial Peptide, LL-37. Biochemistry, 42(21), 6545–6558. · link
6. Henzler-Wildman, K. A., Martinez, G. V., Brown, M. F., & Ramamoorthy, A. (2004). Perturbation of the Hydrophobic Core of Lipid Bilayers by the Human Antimicrobial Peptide LL-37. Biochemistry, 43(26), 8459–8469. · link
7. Fabisiak, A., Murawska, N., & Fichna, J. (2016). LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacological Reports, 68(4), 802–808. · link

References

1. Zasloff M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor.. Proceedings of the National Academy of Sciences. · DOI
2. Dürr U., Sudheendra U., Ramamoorthy A. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes. · DOI
3. Matsuzaki K. (2009). Control of cell selectivity of antimicrobial peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes. · DOI
4. Hancock R., Sahl H. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology. · DOI
5. Merrifield R. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society. · DOI
6. FIELDS G., NOBLE R. (1990). Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research. · DOI
7. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI
8. Rauh M. (2012). LC–MS/MS for protein and peptide quantification in clinical chemistry. Journal of Chromatography B. · DOI